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Research Question? Call the Office of Research at our central number: (413) 794-3391
Lung-MAP study explores alternative 
therapies for cancer treatment
John McCann, MD, Baystate 
Principal Investigator for the Eastern 
Cooperative Oncology Group 
(ECOG)
The D’Amour Center for Cancer Care at 3350 Main Street in Springfield, MA, 
where this and many other cancer trials take place.
With cancer therapy advanc-
ing rapidly, having cancer trials 
at Baystate allows our standard 
of cancer care to stay state-
of-the-art. There are nearly 30 
active clinical trials for cancer 
at Baystate, which is part of 
an interconnected network of 
cancer researchers across our 
region, the country, and the 
world. Lung cancer, the most 
common type of advanced 
cancer, relies heavily on 
clinical trials help to discover 
more effective and less toxic 
treatments.
One of the latest lung cancer 
trials, the Lung-MAP study, is an 
innovative protocol to evaluate 
biomarker-driven therapies and 
immunotherapies in previously 
treated non-small cell lung 
cancer. Like the name of the trial 
suggests, Lung-MAP evaluates 
a patient’s cancer molecular 
profile and provides a “map” of 
the molecular changes that may 
be targets for new treatments. 
This trial offers an opportu-
nity to investigate treatment 
regimens to determine a new 
standard of care. Lung-MAP is 
considered an “umbrella trial”: 
an interconnected network of 
trials subdivided by medication/
treatment type. Depending on 
which branch of lung cancer 
the patient falls under, a specific 
medication or combination of 
medications/therapies is pre-
scribed. One of the treatment 
options under this umbrella is 
immunotherapy. 
“Immunotherapy has been 
a great advance in cancer 
research, and it’s very excit-
ing,” says John McCann, MD, 
Baystate Principal Investigator 
for the Eastern Cooperative 
Oncology Group (ECOG). “With 
certain types of lung cancer, we 
are able to skip chemo entirely 
and go straight to immunother-
apy.” Both chemotherapy and 
immunotherapy are adminis-
tered intravenously. Chemo-
therapy targets and damages a 
cancer cell’s ability to multiply, 
which can have adverse effects 
on normal cells and cause 
side effects. On the contrary, 
immunotherapy does not affect 
the cancer cell directly and has 
fewer side effects. Instead, it 
tells the body’s own immune 
cells to identify the cancer cells 
as harmful and attack them, like 
if you had an infection. Molecu-
lar targeting is also a treatment 
option, using medications that 
target the molecular changes in 
cancer cells. Driver mutations 
control the activity of the cancer 
and drugs that attack the driver 
mutation can slow the multipli-
cation of the cells. Since not all 
cancer cells are the same, “it 
is becoming mandatory to see 
what molecular/cellular profiles 
exist within the cancer cells,” 
Dr. McCann says. “Molecular 
abnormalities can be targets 
for new types of treatment.” 
The Lung-MAP trial allows 
the research team to obtain a 
detailed molecular profile by 
sending a patient’s pathology 
specimen out for analysis. If a 
molecular driver is identified, the 
patient may be able to receive 
a new investigation therapy at 
Baystate. This capability allows 
the patient to have cutting-edge 
treatment close to home. 
“It’s very rewarding for the 
patients as well as the inves-
tigators,” adds Dr. McCann. 
“Through these clinical trials, 
patients get to have access 
to medications they wouldn’t 
normally have access to.”
For more information 
about the Lung-MAP study 
and other cancer trials, con-
tact Katie Colbeck, CCRP 
at (413) 794-9875 or visit 
baystatehealth.org/patients/
learn-about-clinical-trials.
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Engaging Springfield students in research
Sallie Schneider, PhD
With a grant from the National 
Institute of Environmental Health 
Sciences (NIEHS), Baystate 
investigator Sallie Schneider, 
PhD and her team will be able 
to bring hands-on research 
experience to students in 
Springfield’s middle and high 
schools. As part of the National 
Institutes of Health (NIH), NIEHS 
supports a research grant 
at Baystate that studies how 
environmental exposures affect 
growth and development of 
breast cancer. One goal of the 
grant focuses on community 
involvement, aiming to promote 
education among local students. 
To that end, she is collaborating 
with Ron St. Armand, Director of 
Science in the Springfield Public 
School System (SPSS) and Peter 
Blain, BSEP, to devise a city-
wide research project to study 
exposures to chemicals that act 
like estrogen during puberty 
and their effects on changes 
in the breast, as well as other 
organs. SPSS received a Mas-
sachusetts Life Science grant to 
purchase equipment, supplies 
and to develop a professional 
development course aimed 
at supporting this community 
initiative. 
This summer, Dr. Schneider 
will begin educating Springfield 
high school science teachers 
in a professional development 
course to prepare them for the 
upcoming school year. She will 
help teachers to incorporate 
research into their current 
biology curriculum and develop 
critical thinking ability. In the fall 
she will provide reagents so 
that each student can analyze 
a small aspect of the study. 
The goal will be to combine 
the analyses performed across 
the schools and classrooms 
to have a better perspective 
of changes that occur when 
exposed to chemicals during 
critical periods. Dr. Schneider 
hopes the students feel excited 
or empowered by contributing 
to a research study, but more 
importantly that they have a new 
understanding for how various 
chemicals in the environment 
can impact their health. The 
school has suggested four 
strategic priorities that will 
ensure that effective instruction 
occurs in every class and that 
there are shared expectations 
for all students. These priorities 
include: 
• Coaching, developing and 
evaluating educators based 
on a clear vision of strong 
instruction
• Implementing a consistent, rig-
orous curriculum built on com-
mon standards with common 
unit assessments
• Deploying data that is timely, 
accurate and accessible to 
make decisions for students, 
schools and the district
• Strengthening social, emo-
tional and academic safety nets 
and supports for all students 
and families
“This is a fantastic collabora-
tion between Baystate and 
the Springfield schools,” says 
Dr. Schneider. “We are invest-
ing time to involve students in 
research in hopes that the real 
life experience will help them 
to get excited about science 
and increase awareness.” It is 
Dr. Schneider’s hope that AP 
students will eventually visit the 
Baystate Research labs to do 
simple stains of cells and learn 
more about hands-on biomedi-
cal research themselves. 
“We are excited to see what 
will come out of this grant,” she 
concludes. “It’s a collaboration 
that our research department 
hasn’t gotten to do before.”
New Faces of Research
Maria Valdez, BS
Research Assistant l
Clinical Trials Office
EILEAN ATTWOOD, MD
Supportive Pregnancy Care, ObGyn/
March of Dimes
NORMAN DESCHAINE
2019 Ryan White, HIV/AIDS/Holyoke 
Health Center, Inc./HRSA; 2019 Con-
necticut River Valley Farmworker Health 
Program, Community Health Centers/MA 
League Community Health Centers/HRSA
ROSA FELDMAN
Baystate Noble Opioid Treatment and 
Prevention Program, MA Dept. of Public 
Health
ASHEQUL ISLAM, MD
Assessment of the CARILLON Mitral Con-
tour System in Treating Functional Mitral 
Regurgitation Associated with Heart 
Failure The CARILLON Trial, Cardiology/
Cardiac Dimensions, Inc.
TARA LAGU, MD
Improving Access to Care for Patients 
with Lower Limb Mobility Impairment, 
HCQ/Baystate Health, Inc./RPAP
PETER LINDENAUER, MD
SHIFT-CARE Challenge Health 
Homes BMC, HCQ/ACO/Health Policy 
Commission
QUINN PACK, MD
Exercise Prescription in Cardiac Reha-
bilitation: A Pilot Randomized Controlled 
Trial, HCQ/RPAP/Baystate Health, Inc.
VICTOR PINTO-PLATA, MD
Study of Pulmonary Rehabilitation 
In Nintedanib Treated Patients with 
IPF:Improvements in Activity, Exercise 
Endurance Time, and QoL, Critical Care/
Boehringer Ingelheim Pharm
SALLIE SCHNEIDER, PHD
Studying EDC exposure on macrophage 
function and ER negative breast cancer 
progression, PVLSI/University of Wiscon-
sin/Nat. Institutes of Health (NIH)
CHANDRIKA SRIDHARAMURTHY, MD
Collaborative Care for Kids (CATCH 
Grant), Pediatrics/American Academy of 
Pediatrics
JAY STEINGRUB, MD
.VICTAS - Vitamin C, Thiamine and 
Steroids in Sepsis, Critical Care/Johns 
Hopkins University/Marcus Foundation; 
HostDx Sepsis in the Diagnosis and 
Prognosis of Emergency Department 
Patients with Acute Respiratory Infections: 
a Multicenter Pilot Study, Critical Care/
Inflammatix, Inc.
MARK TIDSWELL, MD
Pilot study of non-invasive ventilatory 
support for acute hypoxemic respira-
tory failure: High flow nasal cannula vs. 
Helmet vs. Mask, Critical Care/Baystate 
Health, Inc./RPAP
Select Recent Awards
Kamal Faridi
Biostatistician
IHDPS
Vicky MacLeod, BA
Research Assistant l
Clinical Trials Office
Ali Griffin, BSN
Clinical Research 
Regulatory Specialist
Clinical Trials Office
Paula Pelletier, MS, RN
Clinical Research 
Nurse Coordinator
Clinical Trials Office
Jennifer Blanquart
Clinical Research 
Coordinator I
Baystate Regional 
Cancer Program
Camron Clark
Clinical Research 
Coordinator I
Baystate Regional 
Cancer Program
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Andrews CM, Abraham AJ, 
Grogan CM, Westlake MA, 
Pollack HA, Friedmann PD. 
Impact of Medicaid Restrictions 
on Availability of Buprenor-
phine in Addiction Treatment 
Programs. Am J Public Health. 
2019 Mar;109(3):434-436.
Keteyian SJ, Ehrman JK, Fuller 
B, Pack QR. Exercise Testing 
and Exercise Rehabilitation for 
Patients With Atrial Fibrillation. 
J Cardiopulm Rehabil Prev. 
2019 Mar;39(2):65-72.
Coute RA, Nathanson BH, 
Panchal AR, Kurz MC, Haas 
NL, McNally B, Neumar RW, 
Mader TJ. Disability-Adjusted 
Life Years Following Adult 
Out-of-Hospital Cardiac Arrest 
in the United States. Circ 
Cardiovasc Qual Outcomes. 
2019 Mar;12(3):e004677
Adamidis A, Cantas-Orsdemir 
S, Tsirka A, Abbott MA, 
Visintainer P, Tonyushkina 
K. Apparent Mineralocorti-
coid Excess in the Pediatric 
Population: Report of a Novel 
Pathogenic Variant of the 
11β-HSD2 Gene and System-
atic Review of the Literature. 
Pediatr Endocrinol Rev. 2019 
Mar;16(3):335-358.
Lagu T, Norton CM, Russo LM, 
Priya A, Goff SL, Lindenauer 
PK. Reporting of Patient Experi-
ence Data on Health Systems’ 
Websites and Commercial 
Physician-Rating Websites: 
Mixed-Methods Analysis. J 
Med Internet Res. 2019 Mar 
27;21(3):e12007.
Singh R, Douglass LM, 
O’Shea TM, Stafstrom CE, 
Allred EN, Engelke S, Shah B, 
Leviton A, Hereen TC, Kuban 
KCK; ELGAN Study Group. 
Antecedents of epilepsy and 
seizures among children born 
at extremely low gestational 
age. J Perinatol. 2019 Mar 27.
Attaar A, Luketich JD, 
Schuchert MJ, Winger DG, 
Sarkaria IS, Nason KS. Pro-
longed Air Leak After Pulmo-
nary Resection Increases Risk 
of Noncardiac Complications, 
Readmission, and Delayed 
Hospital Discharge: A Propen-
sity Score-adjusted Analysis. 
Ann Surg. 2019 Feb 15.
Soares WE 3rd, Wilson D, 
Gordon MS, Lee JD, Nunes EV, 
O’Brien CP, Shroff M, Fried-
mann PD. Incidence of future 
arrests in adults involved in 
the criminal justice system with 
opioid use disorder receiving 
extended release naltrexone 
compared to treatment as 
usual. Drug Alcohol Depend. 
2019 Jan 1;194:482-486.
Pack QR, Priya A, Lagu T, 
Pekow PS, Berry R, Atreya 
AR, Ades PA, Lindenauer PK. 
Cardiac Rehabilitation Utiliza-
tion During an Acute Cardiac 
Hospitalization: A NATIONAL 
SAMPLE. J Cardiopulm Rehabil 
Prev. 2019 Jan;39(1):19-26.
Walkey AJ, Shieh MS, Pekow 
P, Lagu T, Lindenauer PK. 
Changing heart failure coding 
practices and hospital risk-
standardized mortality rates. J 
Card Fail. 2019 Jan 7.
Soares WE 3rd, Price LL, 
Prast B, Tarbox E, Mader TJ, 
Blanchard R. Accuracy Screen-
ing for ST Elevation Myocardial 
Infarction in a Task-switching 
Simulation. West J Emerg Med. 
2019 Jan;20(1):177-184.
Aloia TA, Jackson T, Ghaferi A, 
Dort J, Schwarz E, Romanelli J. 
Developing minimally invasive 
procedure quality metrics: one 
step at a time. Surg Endosc. 
2019 Jan 22.
Sharma SK, Bolduan RW, Patel 
MR, Martinsen BJ, Azemi T, 
Giugliano G, Resar JR, Mehran 
R, Cohen DJ, Popma JJ, Waks-
man R. Impact of calcification 
on percutaneous coronary 
intervention: MACE-Trial 1-year 
results. Catheter Cardiovasc 
Interv. 2019 Jan 25.
Vaidya R, Wilson D, Paris Y, 
Madore L, Singh R. Use of 
acetaminophen for patent 
ductus arteriosus treatment: 
a single center experience. J 
Matern Fetal Neonatal Med. 
2019 Jan 28:1-7.
Notable Recent Published Papers
Contact Baystate’s Health Science Library for more information at libraryinfo.bhs.org/home
The field of Infectious 
Diseases (ID) is one of sev-
eral subspecialties of Internal 
Medicine. It differs from other 
fields in Internal Medicine, 
such as cardiology, pulmonary, 
nephrology etc., which primarily 
focus on a single organ system. 
Since microbes (including 
bacteria, viruses, fungi, para-
sites) can affect a single organ 
(for example pneumonia) or the 
entire body (systemic infection), 
such as bacterial sepsis or HIV, 
ID doctors need to be have 
knowledge of the whole body. 
They interact with nearly all 
medical specialties and a treat a 
wide spectrum of patients.
Since new types of infec-
tions are continuously being 
discovered, ID doctors need to 
constantly stay up to date. In 
only the last few years, numer-
ous infections have been either 
discovered or have affected 
new populations or new clinical 
manifestations. West Nile virus, 
SARS, bird flu, Middle East 
Respiratory Syndrome (MERS), 
Zika virus, Chikungunya fever, 
are only a few of these. The 
clinical manifestations and 
treatment of newly discovered 
infections, as well as the ability 
of most bacteria and viruses to 
develop resistance to medica-
tions, creates a continuous need 
for both laboratory and clinical 
researchers. New treatments 
need to be evaluated in several 
phases of clinical trials and often 
require the inclusion of several 
thousand patients prior to 
approval for the general public.   
“It seems that every time 
we are about to catch up, the 
microbes seem to get ahead,” 
says Dr. Daniel Skiest, Director 
of ID Clinical Research and the 
Adult HIV/AIDS Program at Bay-
state Health and Vice Chair for 
Academic Affairs in the Depart-
ment of Medicine. “Research will 
always be an important aspect 
of ID.” 
Dr. Skiest gained experience 
in HIV clinical trials as a faculty 
member of University of Texas 
Southwestern Medical Center. 
“Our HIV clinic cared for 
3,500 patients and we were 
able to enroll many patients in 
novel and ultimately lifesaving 
treatments for HIV in the mid to 
late 1990s and the early 2000s,” 
he says. Shortly after being 
recruited to Baystate in 2005, 
Dr. Skiest started the ID trials 
unit. To date, Dr. Skiest and his 
team have enrolled over 300 
individuals in clinical studies, 
mostly in HIV, but also influenza, 
pneumonia and hepatitis C.
One trial in progress, the 
REPRIEVE trial, has recruited 
7,500 participants from over 100 
sites across the globe. Thirty of 
these participants are enrolled 
at Baystate. REPRIEVE is the 
largest study ever involving 
HIV-infected individuals and is 
sponsored by the NIH (National 
Institutes of Health). This study 
will evaluate whether the use of 
a statin medication will prevent 
vascular events (heart attacks, 
strokes) in patients with HIV 
between 40-75 years old and 
without known heart disease. 
The study is important since 
individuals living with HIV are 
50-100% more likely to develop 
heart disease than people 
without HIV. 
Another ongoing study, The 
Respiratory Virus Hospitalization 
Study (FLU 003), an interna-
tional observational study, 
aims to better characterize the 
manifestations and complica-
tions of influenza. It includes 
adults hospitalized with influ-
enza and other flu-like illness. 
Since it began eight years ago 
Baystate has enrolled over 130 
individuals. Participants must be 
18 years or older and have been 
admitted to the hospital for influ-
enza or a targeted non-influenza 
viral respiratory infection.
Other ongoing studies are a 
study of novel 2 drug regimen 
for treatment of HIV (GEMINI), 
a study of novel 3 drug com-
bination treatment for HIV 
(Gilead-1489) and the Coopera-
tive Re-Engagement Controlled 
Trial (CoRECT, sponsored by the 
CDC), which seeks to improve 
outcomes for HIV-infected indi-
viduals who are not in care.
The research team includes 
Dr. Armando Paez, Dr. Durane 
Walker, and Caroline Hinostroza 
(regulatory specialist), Mary Lee 
Bertrand, RN (study coordinator), 
Victoria Cobb (study coordina-
tor), and Maribella Gonzalez 
(research assistant). They are 
located at 3300 Main Street, 
which is also the location of the 
main ID clinic.
“It’s exciting and gratifying to 
be able to play a role in bringing 
new treatments to our patients,” 
concludes Dr. Skiest.
For questions and more infor-
mation about these and other 
ID trials, call (413) 794-5376.
Daniel Skiest, MD, FACP, FIDSA
Infectious diseases clinical research with Dr. Daniel Skiest
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Carolanne Lovewell, RLATG, 
CPIA, Director of the Baystate 
Research Facility and Pioneer 
Valley Life Sciences Institute, 
takes a break to read the last 
issue of The Innovator with 
Minnie Mouse during a recent 
trip to Walt Disney World. 
The Innovator travels to Orlando
InnovatorThe
We are interested in ensuring that Baystate employees and patients 
(and their families) are aware of the important research that goes on at 
Baystate and how it contributes to better patient care. The Innovator 
welcomes feedback and story ideas. Contact Allison Litera at allison.
litera@baystatehealth.org to submit yours.
Common Rule implements first changes since 1991
Jennifer Pacheco, MPH, CIM, CIP
The Office of Research held their annual holiday gathering at the Munich 
Haus in Chicopee on January 24, 2019.
Holiday celebration held in January
The Common Rule is a 
framework for federally funded 
research studies in the United 
States that ensures ethical stan-
dards and protects human par-
ticipants in clinical research. As 
of January 20, 2019, the Com-
mon Rule implemented new 
changes for the first time since 
its inception. This long-overdue 
change is much-needed, con-
sidering the scientific and tech-
nologic advancements since the 
early 1990s. Any project already 
approved under previous rule 
prior to January 2019 will remain 
as such.
Changes to the Common Rule 
as of January 2019 include: 
• Revised, comprehensive 
consent forms 
• Fewer details required annu-
ally for smaller, less-risky studies
• Any multi-site studies will 
be housed under a single IRB 
(January 2020)
Although the Common Rule 
changes are finally imple-
mented, direction is still needed. 
“How we go about handling 
the changes in Common Rule 
will be tricky,” explains Jennifer 
Pacheco, Director of Healthcare 
Research Compliance and Chief 
Research Compliance Officer 
at Baystate Health. “There is no 
federal guidance or ‘rule book’ 
yet and that is the biggest chal-
lenge. Until we are issued the 
federal guidelines document, 
we are unsure if our interpreta-
tion will be the same as other 
institutions.” Since there is more 
documentation and precision in 
the new rule, it doesn’t reduce 
the administrative burden as 
hoped. Fortunately, the Com-
mon Rule will continue to 
change, with a new minimum 
revision period of every four 
years. This will introduce more 
frequent opportunities for 
growth and development of the 
rules already in place.
“This means that our research 
community needs to be open 
to change from time to time,” 
adds Pacheco. Overall, Pacheco 
supports the majority of the 
changes. She suggests keep-
ing an ear open for various 
educational series presented 
by the Baystate IRB/HRPP 
throughout the year. If you’d like 
to learn more about the IRB/
HRPP, visit baystatehealth.org/
education-research/research/
for-researchers.
(L-R) Vida Rastegar, Aixa Perez-Carabello, Adele Miller, Judith Pride, RN, MSHS, CCRP, 
CCRC, CIP, Katherine Colbeck, CCRP, Laura Sorci, and Bella Gonzalez 
(L-R) Alexander Knee, Randall Hoskinson Jr., Nicholas Jabbour, MD, Peter Friedmann, 
MD, MPH, DFASAM, FACP, Sue Decelle, Marc Labrie, Susan Garrow-Sloan, RN, CCRP
(L-R) Catherine McDougal, CCRP, CIP, Roxanne Labonte, Alexa Lopez, Marcia Winseck, 
Rebecca Greene, CPIA, Paul Visintainer, PhD, Joe Jerry, PhD
Research & Education Celebration
May 15, 2019 • 8 AM - 6 PM • Chestnut Conference Center
WORKSHOPS:
• Visualizing Complexity In Medical Training & Care
• Research Mentorship For Faculty: A Panel Discussion
• One Scholarly Approach, Many Educational Innovations
• Qualitative Data Analysis 101
• Generating Rigorous Qualitative Insights
• Strategies For Writing Up Your Educational 
Innovations: A Workshop To Get You Started
• Research On The Cheap
• Building Sustainability In Times Of Uncertainty
• How To Be An Efficient Site Investigator
POSTER VIEWING/SESSION • AWARD CEREMONY
FEATURED PRESENTER:
Kori LaDonna, PhD
Department of Innovation in Medical 
Education, University of Ottawa
For more information/full schedule call 413-
794-3391 or visit baystatehealth.org/REC
